Education
About Us
Working with TipRanks
Follow Us
Marvel Biosciences Corp (TSE:MRVL)
:MRVL
RESEARCH TOOLSreports
Total Valuation
Marvel Biosciences Corp has a market cap or net worth of C$3.81M. The enterprise value is C$8.59M.
Market CapC$3.81M
Enterprise ValueC$8.59M
Share Statistics
Marvel Biosciences Corp has 44,803,730 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding44,803,730
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Marvel Biosciences Corp’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is 0.11%.
Return on Equity (ROE)<0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)0.11%
Return on Capital Employed (ROCE)<0.01
Revenue Per Employee―
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Marvel Biosciences Corp is -2.91K. Marvel Biosciences Corp’s PEG ratio is 29.06.
PE Ratio-2.91K
PS Ratio0.00
PB Ratio-1.70
Price to Fair Value-1.70
Price to FCF-4.07
Price to Operating Cash Flow-4.07
PEG Ratio29.06
Income Statement
In the last 12 months, Marvel Biosciences Corp had revenue of 0.00 and earned ― in profits. Earnings per share was 0.00.
Revenue0.00
Gross Profit0.00
Operating Income―
Pretax Income―
Net Income―
EBITDA0.00
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -989.41K and capital expenditures 0.00, giving a free cash flow of -989.41K billion.
Operating Cash Flow-989.41K
Free Cash Flow-989.41K
Free Cash Flow per Share-0.02
Dividends & Yields
Marvel Biosciences Corp pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.27
52-Week Price Change-46.67%
50-Day Moving Average0.13
200-Day Moving Average0.13
Relative Strength Index (RSI)33.56
Average Volume (3m)42.00K
Important Dates
Marvel Biosciences Corp upcoming earnings date is Jun 19, 2025, TBA Not Confirmed.
Last Earnings DateMar 31, 2025
Next Earnings DateJun 19, 2025
Ex-Dividend Date―
Financial Position
Marvel Biosciences Corp as a current ratio of 0.31, with Debt / Equity ratio of -48.21%
Current Ratio0.31
Quick Ratio0.31
Debt to Market Cap0.36
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Marvel Biosciences Corp has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Marvel Biosciences Corp EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -5.22.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow-5.22
EV to Operating Cash Flow-5.22
Balance Sheet
Marvel Biosciences Corp has C$59.53K in cash and marketable securities with C$1.71M in debt, giving a net cash position of C$1.65M billion.
Cash & Marketable SecuritiesC$59.53K
Total DebtC$1.71M
Net CashC$1.65M
Net Cash Per ShareC$0.04
Tangible Book Value Per Share-C$0.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Marvel Biosciences Corp is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―